Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Brain Metastases From HER2 and Breast Cancer: early-phase trial registry

1 of 1 indexed Brain Metastases From HER2 and Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Brain Metastases From HER2 and Breast Cancer: 1 US clinical trial tracked, 1 recruiting.

Brain Metastases From HER2 and Breast Cancer is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Iambic Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition brain-metastases-from-her2-and-breast-cancer

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Brain Metastases From HE (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Brain Metastases From HER2 and Breast Cancer

Brain Metastases From HER2 and Breast Cancer lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Brain Metastases From HER2 and Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Brain Metastases From HER2 and Breast Cancer is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Brain Metastases From HER2 and Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

IAM1363 Drug
1 trials

US sites by state

Facility locations filed on Brain Metastases From HER2 and Breast Cancer trials. A trial with sites in several states counts in each.

Tennessee 1 trials
Oregon 1 trials
Oklahoma 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
North Carolina 1 trials
Missouri 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Brain Metastases From HER2 and Breast Cancer page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Brain Metastases From HER2 and Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Iambic Therapeutics sponsors the most Brain Metastases From HER2 and Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Iambic Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Brain Metastases From HER2 and Breast Cancer condition card totals 1 registered trials; most-linked intervention IAM1363; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.